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SUMMARY
Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant
JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to
myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors
promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immuno-
compromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly in-
hibited JAK2V617F+ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic
transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with ery-
throid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phos-
phorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F+ MPDs in clinical trials.INTRODUCTION
Myeloproliferative disorders, such as PV, essential thrombocy-
themia (ET), and myelofibrosis (MF), are clonal hematopoietic
disorders typified by overproduction of terminally differentiated
cells in part as a result of hypersensitivity of marrow progenitor
cells to hematopoietic growth factors (Adamson et al., 1976;
Cashman et al., 1988; Dai et al., 1992; Fialkow et al., 1981; Gilli-
land et al., 1991; Jamieson et al., 2006; Prchal and Axelrad, 1974;
Ugo et al., 2004). Clonal derivation of MPDs from a primitive he-
matopoietic progenitor was first suggested by studies demon-
strating the same glucose-6-phosphate dehydrogenase
(G6PD) allele in PV erythrocytes, granulocytes, and platelets
(Fialkow et al., 1981) and later confirmed by phosphoglycerate
kinase gene PCR that revealed clonal involvement of themyeloidand erythroid lineages in female PV patients (Gilliland et al.,
1991). Several recent reports provided critical insight into the
molecular events involved in the development of PV by identify-
ing a mutation (V617F) that constitutively activates the JAK2
tyrosine kinase in the majority of patients with PV and approxi-
mately 50% of patients with ET and idiopathic myelofibrosis
(MF) (Baxter et al., 2005; James et al., 2005; Kralovics et al.,
2005; Levine et al., 2005). JAK2V617F gene expression in the
Ba/F3 growth factor-dependent cell line resulted in erythropoie-
tin (EPO) hypersensitivity and growth factor-independent sur-
vival (James et al., 2005). Moreover, transplantation of mouse
marrow cells transduced with the JAK2V617F mutant allele
into lethally irradiated recipients resulted in erythrocytosis typical
of PV (James et al., 2005). In addition, mice transplanted with
JAK2V617F-expressing cells developed a PV-like disease thatSIGNIFICANCE
Increased morbidity and mortality rates associated with JAK2+ MPDs have provided the impetus for developing small-
molecule JAK2 inhibitors. Moreover, JAK2+MPDs represent an important paradigm for understanding themolecular under-
pinnings of hematopoietic progenitor cell-fate decisions. We identified an orally bioavailable, selective JAK2 inhibitor,
TG101348, which inhibits the aberrant erythroid differentiation potential of PV progenitors in vitro and in a preclinical bio-
luminescent xenogeneic transplantation model of human PV. This research provides direct in vivo evidence suggesting
that JAK2V617F is both necessary and sufficient to drive aberrant human PV progenitor erythroid differentiation through
enhanced GATA-1 transcription. This process is potently reversed by TG101348, thereby providing the impetus for its
use in clinical trials for JAK2+ MPDs.Cancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc. 321
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Selective Inhibition of JAK2 in PV Progenitorsprogressed to myelofibrosis in a manner analogous to human PV
(Wernig et al., 2006). These studies support a critical role for
JAK2V617F in the pathogenesis of a large proportion of MPDs
(Kaushansky, 2005).
Although JAK2V617F-driven MPDs such as PV, ET, and MF
have a combined incidence that is 5-fold higher than chronic my-
eloid leukemia (CML) (Tefferi and Gilliland, 2007), the first leuke-
mia to be associated with a pathognomic molecular abnormality
at the hematopoietic stem cell level (Daley et al., 1990; Fialkow
et al., 1977; Holyoake et al., 1999; Jamieson et al., 2004) and
the first cancer to be treated with molecularly targeted therapy
(Druker et al., 2006; Kantarjian et al., 2006; Talpaz et al., 2006),
there has been no treatment developed to date that selectively
inhibits JAK2 kinase activity (Tefferi and Elliott, 2007). While
JAK2V617F+ PV and ET have a lower rate of progression to acute
leukemia than CML, both quality and quantity of life are detri-
mentally affected by a high prevalence of major thrombotic
events (Tefferi and Elliott, 2007). In addition, primary myelofibro-
sis and acute myelogenous leukemia (AML) or myelofibrosis that
develops following sustained myeloproliferation in JAK2V617F+
PV or ET are relatively recalcitrant to current forms of treatment,
thereby providing the impetus for developing selective JAK2
inhibitors (Harrison et al., 2005; Kiladjian et al., 2006; Tefferi
et al., 2006).
Previously, FACS analysis of early phase PV patient samples
revealed an expansion in the number of cells with a HSC pheno-
type (CD34+CD38CD90+Lin) suggesting that PV HSC had en-
hanced proliferative potential (Jamieson et al., 2006). In hemato-
poietic progenitor assays, PV HSC gave rise to a preponderance
of large erythroid colonies that expressed the JAK2V617F muta-
tion (Jamieson et al., 2006). These results suggested that
the JAK2V617F mutation had an inherent capacity to skew
differentiation of PV HSC toward an erythroid fate (Jamieson
et al., 2006). However, the molecular mechanisms mediating
JAK2V617F progenitor cell-fate decisions were not elucidated
(Jamieson et al., 2006). Moreover, the capacity of a selective
JAK2 inhibitor to prevent JAK2-driven engraftment in xenoge-
neic transplantation models of human PV had not been investi-
gated.
In this study, we assessed the capacity of JAK2V617F to alter
human hematopoietic progenitor cell-fate decisions both in vitro
and in a bioluminescent xenogeneic transplantationmodel of hu-
man PV. We also examined erythroid differentiation potential in
the presence or absence of a selective small-molecule ATP-
competitive JAK2 inhibitor, TG101348, as a means of preclini-
cally assessing its potential efficacy as a molecular-targeted
therapy for JAK2-driven MPDs. To investigate possible mecha-
nisms of action, we examined the capacity of TG101348 to in-
hibit JAK2 driven STAT5-phosphorylation and AKT-mediated
GATA-1 S310 phosphorylation as well as GATA-1 and PU.1 tran-
scription factor ratios known to regulate hematopoietic progen-
itor cell-fate decisions (Zhao et al., 2006).
RESULTS
In Vitro Inhibition of PV Progenitor Erythroid
Differentiation by TG101348
TG101348 (Figure 1A) was designed and synthesized at Targe-
Gen using structure based drug design methods to inhibit322 Cancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc.JAK2 and JAK2V617F kinase (IC50 = 3 nM for both; data not
shown). In contrast to other currently available inhibitors,
TG101348 does not inhibit other closely related kinases such
as JAK3 (IC50 = 1040 nM; data not shown). In five independent
experiments, hematopoietic stem cells (HSC; CD34+CD38
CD90+Lin) and common myeloid progenitor (CMP; CD34+
CD38+CD123+CD45RALin) cells from three JAK2V617F+ PV
patients (Table 1) were FACS-sorted (Jamieson et al., 2006;
Manz et al., 2002) into methylcellulose supplemented with hu-
man cytokines and increasing concentrations of TG101348. Dif-
ferential colony counts were performed on day 14. These ex-
periments demonstrated that the propensity of PV progenitors
to differentiate along the erythroid lineage was significantly
inhibited by 300 nM of TG101348 (BFU-E; p = 0.02), as
was the formation of mixed colonies (CFU-Mix; p = 0.05)
(Figure 1B). No significant inhibition of other colony types was
observed at this dose although there was a trend toward inhibi-
tion of CFU-GM (p = 0.17), which did not reach statistical signif-
icance. Three experiments revealed dose-dependent sensitivity
of erythroid colonies (Figure 1C) to the inhibitory effects of
TG101348 relative to other colony types (Figures S1A and
S1B available online). Colonies were analyzed for JAK2V617F+
expression by a direct semiquantitative sequencing method
and revealed a reduction in mutant allele frequency, although
individual variability in sensitivity to TG101348 was detected
(Figure 1C).
In Vitro Inhibition of JAK2V617F-Driven Erythroid
Differentiation with TG101348
The role of JAK2V617F in skewing differentiation potential was
investigated by lentivirally-enforced expression (Naldini et al.,
1996) of JAK2V617F or wild-type JAK2 in normal cord blood pro-
genitors in hematopoietic progenitor assays. JAK2V617F-ex-
pressing cord blood progenitors gave rise to a preponderance
of erythroid (BFU-E) colonies, while wild-type JAK2 induced
more mixed (CFU-Mix) colony formation over that of backbone
vector controls (Figure 2A; n = 4 experiments). PCR performed
with primers specific for lentivirally introduced JAK2 (mJAK2) fol-
lowed by sequencing was used to verify transduction of colonies
with the lentiviral vectors (Figure 2B). In subsequent in vitro ex-
periments (n = 4), lentiviral backbone-, JAK2V617F-, or wild-
type JAK2 (WT JAK2)-transduced human cord blood HSC
were treated with or without 300 nM of TG101348 and plated
onto methylcellulose supplemented with human cytokines.
These experiments demonstrated selective inhibition of
JAK2V617F skewed erythroid colony formation with TG101348
(Figure 2C).
Inhibition of Human PV Progenitor Erythroid
Engraftment by TG101348
The capacity of PV stem and progenitor cells to give rise to hu-
man erythroid engraftment compared with their normal coun-
terparts was assessed in a bioluminescent xenogeneic trans-
plantation model involving intrahepatic transplantation of
neonatal highly immunocompromised (RAG2/gc
/) mice
(Traggiai et al., 2004) with luciferase-transduced (Breckpot
et al., 2003) human progenitor cells (Figure 3A). While biolumi-
nescent imaging demonstrated comparable rates of engraft-
ment between normal and PV progenitors (Figure 3B), FACS
Cancer Cell
Selective Inhibition of JAK2 in PV ProgenitorsFigure 1. In Vitro Inhibition of PV Progenitor Erythroid Differentiation by TG101348
(A) Structure of TG101348.
(B) In five experiments, PV hematopoietic stem cells (HSC) and commonmyeloid progenitors (CMP) from JAK2V617F+ PV patients (n = 3 patients) were FACSAria
sorted directly into 96-well plates containing methylcellulose supplemented with human cytokines and treated with 0 or 300 nM of TG101348 (+TG). Differential
colony counts were performed on day 14.
(C) Upper panel: representative photomicrographs of PV progenitor colonies (scale bar, 100 mm) treatedwith 0, 30, or 100 nMof TG101348 and the corresponding
JAK2V617F allele frequency (% V617F) determined by sequencing on pooled colonies.
Lower panel: in three experiments, sequencing analysis was used to determine JAK2V617F allele frequency in pooled HSC colonies treated with 0 or 300 nM of
TG101348.analysis of engrafted hematopoietic organs revealed a propen-
sity for in vivo erythroid differentiation by PV progenitors
in hematopoietic organs of transplanted mice (Figure 3C).
In four separate experiments, oral gavage administration
of TG101348 (120 mg/kg) significantly (p = 0.02) inhibited PV
progenitor erythroid differentiation in vivo (Figure 3D). More-
over, sequencing analysis of hematopoietic tissues derived
from PV progenitor-engrafted mice revealed a corresponding
diminution of JAK2V617F expression following TG101348 treat-
ment (Figure S2).
Selective Inhibition of JAK2V617F-Driven Erythroid
Engraftment
We investigated whether enhanced PV progenitor erythroid en-
graftment was dependent on JAK2V617F or wild-type JAK2 ex-
pression and whether this engraftment was susceptible to inhibi-
tion with TG101348. In these experiments, normal cord blood
progenitors were transduced with backbone, JAK2V617F, or
wild-type JAK2 and transplanted intrahepatically into neonatal
RAG2/gc
/ (Traggiai et al., 2004) recipients (Figure S3). Fol-
lowing 12 days of oral gavage treatment with TG101348
(120 mg/kg), quantitative bioluminescence imaging analysis re-
vealed reduced engraftment (p = 0.08) by JAK2V617F-express-
ing progenitors compared with backbone (p = 0.61) and wild-
type JAK2 (p = 0.67) progenitor-transplanted mice (Figure 4A).
FACS analysis revealed a significant inhibition of JAK2V617F-
driven erythroid engraftment in TG101348-treated transplant re-
cipients (p = 0.037) while wild-type JAK2 (p = 0.077) and back-
bone (p = 0.27) derived human erythroid engraftment were notsignificantly reduced (Figure 4B). These in vivo studies sug-
gested that the enhanced erythroid engraftment potential of
JAK2V617F-transduced cord blood progenitors was more sen-
sitive to inhibition by TG101348 than wild-type JAK2-transduced
progenitors. While TG101348 reduced human engraftment in
bone marrow, it did not inhibit thymic T cell engraftment by
JAK2V617F-expressing progenitors (Figures S4A and S4B).
Since JAK3 is required for T cell development, these observa-
tions further emphasize the selectivity of TG101348 toward
JAK2.
JAK2-Driven Erythroid Signal Transduction Pathways
Are Inhibited by TG101348
The mechanism of JAK2V617F-enhanced erythroid differentia-
tion was investigated by Q-PCR to detect changes in erythroid
(GATA-1), and myeloid (PU.1) transcription factor transcripts in
PV progenitors (Figure 5A) (Galloway et al., 2005; Hsu et al.,
2004). While there were no appreciable differences in PU.1
transcript levels between PV and normal progenitors (p =
0.44), there was a significant increase (p = 0.049) in GATA-1
expression by PV progenitors in keeping with their enhanced
erythroid differentiation potential (Figure 5A). Similarly, lentiviral
transduction of JAK2V617F enhanced expression of GATA-1
but suppressed expression of FOG-1, a megakaryocytic tran-
scription factor, further skewing the transcriptome profile to-
ward enhanced erythroid differentiation (data not shown) (De-
coninck et al., 2000; Galloway et al., 2005; Hsu et al., 2004).
JAK2V617F enhancement of GATA-1 in relation to PU.1
transcripts and inhibition of FOG-1 expression was reversedCancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc. 323
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Patient
Number Sex/Age Date WBC H/H Plts (mm3)
Spleen Size
(cm below LCM)
Treatment at Time
of Sample Acquisition
01 M/68 8/17/05 13 18.7/57.6 461 3 ASA
02a M/62 7/11/05 70.8 12.4/41.7 903 9 hydroxyurea 1 gm +
phlebotomy + coumadin
03 F/55 5/23/05 15 15.5/49.5 666 0 ASA + phlebotomy
04 F/60 5/26/06 17.6 12.3/39 198 2 ASA + phlebotomy + Plavix
05 F/42 6/28/06 16.9 20.3/62 574 7 ASA + phlebotomy
06 M/60 6/09/06 8.6 16/51.8 132 0 PV postinduction for AML
07 M/50 5/4/06 13.5 13.5/43.3 724 15 ASA + phlebotomy
5/15/06 12.1 13.4/43.0 702 15 ASA + phlebotomy
5/25/06 13.3 12.5/39.5 679 15 ASA + phlebotomy
Characteristics of seven patients with JAK2V617F+ polycythemia vera (PV) who donated peripheral blood including age, sex, date of sample, hemo-
globin (Hb), white blood cell count, platelet count, spleen size, and treatment at the time of sample acquisition. WBC, white blood cell count at time of
study; H/H, hemoglobin/hematocrit at time of study; Plts, platelet count at time of study; LCM, left costal margin; ASA, aspirin; gm, gram; AML, acute
myelogenous leukemia.
a Developed acute myelogenous leukemia with 24% marrow blasts on 11/06.by TG101348 treatment (Figure 5B) The GATA-1/PU.1 tran-
script ratio decreased significantly to 25% (p = 0.017)
(Figure 5B, left panel) in the TG101348-treated JAK2V617F-
transduced cells, but not in the backbone-transduced cells (p =
0.47). Similarly, in TG101348-treated JAK2V617F-transduced
cells, FOG-1 transcript levels increased by 30% (data not
shown), and the ratio of GATA-1/FOG-1 transcript levels de-
creased significantly by 52% (p = 0.05) (Figure 5B, right panel)
(InStat analysis, two-tailed t test), reversing enhanced erythroid
differentiation.
To better understand the mechanism of TG101348 reversal of
enhanced erythroid differentiation, we analyzed the effect of
TG101348 on JAK2-mediated signaling in a human erythropoie-
tin responsive cell line UT7/EPO (Figure 5C). Notably, TG101348
(at 300 and 600 nM) inhibited STAT5 phosphorylation more ef-
fectively than AG490, a JAK2 and JAK3 inhibitor. Inhibition of
STAT5 phosphorylation was more pronounced with 600 nM
TG101348 than with 50 mM or even 100 mM of AG490 (data not
shown). While AG490 did not affect AKT phosphorylation in
UT7/EPOcells, TG101348 potently inhibited AKT phosphoryla-
tion in a manner similar to a PI-3 kinase inhibitor, LY294002
(20 mM). Analysis of GATA-1 revealed that erythropoietin en-
hanced GATA-1 serine 310 (S310) phosphorylation while
LY294002 inhibited this slightly. In addition, TG101348 reduced
GATA-1 S310 phosphorylation, consistent with potent inhibition
of AKT phosphorylation (Figure 5C). Notably, GATA-1 S310 phos-
phorylation activates GATA-1-mediated transcription of genes in-
volved in erythroid proliferation and differentiation (Zhao et al.,
2006). Thus, inhibition of AKT-regulated GATA-1 S310 phosphor-
ylation and reduced STAT5 phosphorylation provides a potent
mechanism of inhibition of JAK2-mediated signaling pathways
and JAK2V617F-driven erythroid differentiation by TG101348
(Figure 5D).
DISCUSSION
Recently, we combined multicolor FACS analysis and hemato-
poietic progenitor assays with targeted sequencing analysis of324 Cancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc.purified PV HSC and progenitors in order to identify the stage
of hematopoiesis at which the JAK2V617F mutation occurs.
Our data revealed an increase in HSC in PV peripheral blood,
as well as an expansion of the common myeloid progenitor
(CMP) pool and emergence of an IL-3 receptor alpha-high pop-
ulation during disease progression (Jamieson et al., 2006). In
addition, we detected a qualitative alteration in HSC differentia-
tion potential. Moreover, JAK2V617F mutation expression by
PV HSC was clonally transmitted to committed progenitors.
Finally, greater inhibition of HSC erythroid differentiation was
observed with a JAK inhibitor, AG490, in PV than in normal
HSC (Jamieson et al., 2006). These findings suggested that, in
addition to enhanced proliferative capacity, one of the main de-
fects in PV may be altered differentiation potential at the stem
cell level. However, a direct role for JAK2V617F in altering prim-
itive hematopoietic progenitor cell-fate decisions was not
established.
In this study, the role of JAK2V617F in altering hematopoietic
differentiation was demonstrated by lentiviral transduction of
cord blood progenitors with JAK2V617F. As seen with
JAK2V617F+ PV progenitors, only JAK2V617F overexpression
resulted in enhanced erythroid colony formation, while wild-
type JAK2 increased the number of mixed rather than erythroid
colonies compared with backbone vector controls. These data
suggested a direct link between JAK2V617F expression and en-
hanced erythropoiesis in vitro. Furthermore, we demonstrated
that the propensity of JAK2V617F+ PV HSC and progenitors to
differentiate into erythrocytes was selectively blocked by a po-
tent JAK2 inhibitor, TG101348 (TargeGen Inc.). TG101348 is
a small-molecule ATP-competitive inhibitor that occupies the
ATP-binding pocket of JAK2 (J. Cao, C. Chow, E. Dneprovskaia,
L. Hwang, D. Lohse, C.C.M., M. Martin, A. McPherson, G.N.,
M.S.S. Palanki, V.P. Pathak, J. Renick, R.M.S., B.Tam,
B. Zeng, J.D.H., unpublished data). In addition, TG101348 selec-
tively inhibited erythroid colony formation by JAK2V617F-trans-
duced cord blood progenitors indicative of an innate sensitivity
of JAK2V617F-driven erythroid signal transduction pathways
to TG101348 inhibition.
Cancer Cell
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Driven Erythroid Differentiation with
TG101348
(A) Representative photomicrographs (scale bar
100 mm) of day 14 colonies derived from normal
cord blood HSC transduced with no vector, back-
bone vector, JAK2V617F or wild-type JAK2 (WT
JAK2) vector (n = 4 experiments).
(B) Human cord blood HSC-derived colonies were
collected after 14 days in methylcellulose culture,
and lentiviral JAK2 (mJAK2) PCR was used to ver-
ify transduction. In addition, bands were extracted
and sequenced to verify presence ofWT JAK2 and
JAK2V617F.
(C) Human cord blood HSC transduced with lenti-
viral backbone, JAK2V617F, or wild-type JAK2
(WT JAK2) vectors, (25 cells/well with human cyto-
kine supplemented methylcellulose) were treated
with (+) or without () 300 nM of TG101348, and
colonies were scored on day 14. Untransduced
HSC served as a control. Representative of n = 4
experiments.When the in vivo engraftment and differentiation capacity of
human PV progenitors was compared with that of normal cord
blood progenitors in a bioluminescent xenogenic transplantation
model, PV progenitors had similar rates of engraftment but gave
rise to increased numbers of human erythroid (glycophorin A+)
cells in hematopoietic organs of transplanted mice. Similarly,
JAK2V617F-expressing progenitors promoted erythroid engraft-
ment, as had been reported previously with TEL-JAK2 (Kennedy
et al., 2006), in RAG2/gc
/mice, demonstrating a direct cor-
relation between JAK2V617F and in vivo human erythroid cell-
fate decisions. Targeted inhibition of JAK2 with TG101348 by
oral gavage-mediated administration resulted in a significant re-
duction in erythroid engraftment by both JAK2V617F+ PV- and
JAK2V617F-transduced cord blood progenitors, further under-
scoring the sensitivity of JAK2V617F-driven erythroid differenti-
ation to TG101348.
Investigation of the mechanisms linking JAK2V617F expres-
sion to enhanced erythroid differentiation in vitro and in vivo by
quantitative PCR (Q-PCR) demonstrated that FACS-purified PV
stem and progenitor cells harbored higher transcript levels of
GATA-1, an erythroid transcription factor, than PU.1, a myeloid
transcription factor. This Q-PCR analysis indicated that, in PV
primitive progenitors, cell-fate decisions are irrevocably altered
by an imbalance in erythroid, GATA-1, versus myeloid, PU.1,
transcription factors. To determine whether this imbalance was
a consequence of JAK2V617F expression, we transduced nor-
mal cord blood progenitors with JAK2V617F and analyzed tran-
script levels of GATA-1, PU.1, and FOG-1, a megakaryocyte
transcription factor that has been shown to inhibit erythroid for-
mation (Deconinck et al., 2000). Q-PCR analysis following treat-
ment with vehicle or TG101348 in vitro (Galloway et al., 2005;
Hsu et al., 2004) revealed that JAK2V617F-enhanced GATA-1
expression was significantly reduced relative to PU.1 (p =
0.017) and that the ratio of GATA-1 to FOG-1 transcripts also de-
creased significantly (p = 0.05), thereby reestablishing the bal-
ance of transcription factors required for normal primitive pro-
genitor differentiation. Furthermore, western blot analysis of
a human erythropoietin (EPO) responsive cell line, UT7/EPO,
demonstrated that TG101348-inhibited activation of GATA-1regulated transcription by blocking AKT-mediated GATA-1
S310 phosphorylation, potentially providing another mechanism
for restoring a balance in the effects of lineage skewing tran-
scription factors (Zhao et al., 2006). In addition, TG101348 treat-
ment resulted in decreased STAT5 phosphorylation, further ex-
plaining the potency of TG101348 in blocking JAK2-mediated
signaling. Because previous studies involving targeted inhibition
of BCR-ABL in CML demonstrated that hematopoietic stem and
progenitor cells represent a reservoir for relapse, the capacity of
TG101348 to potently inhibit signaling through JAK2V617F at the
primitive progenitor level may be particularly relevant in deter-
mining the successful outcome of MPD clinical trials with JAK2
inhibitors (reviewed in Kaushansky, 2005) (Holyoake et al.,
1999; Jamieson et al., 2004; Kaushansky, 2005; Weissman,
2005).
Recent reports revealed that some MPDs harbor mutations
outside the JAK2V617F region, for example in exon 12 of the
JAK2 gene or in the MPL gene (Pardanani et al., 2007; Pikman
et al., 2006; Scott et al., 2007). However, over 97% of patients
with PV and approximately 50% of patients with ET and myelo-
fibrosis harbor the JAK2V617Fmutation, underscoring its impor-
tance as a therapeutic target (Baxter et al., 2005; James et al.,
2005; Kralovics et al., 2005; Levine et al., 2005). In this study,
inhibition of JAK2 with TG101348 decreased the aberrant
erythroid differentiation potential of JAK2V617F-positive pro-
genitors both in vitro and in a bioluminescent xenogeneic trans-
plantation model. This occurred, in part, because of decreased
GATA-1 transcription as well as inhibition of both STAT5 and
GATA-1 phosphorylation (Zhao et al., 2006). These data suggest
that TG101348, a JAK2 selective tyrosine kinase inhibitor, may
be an excellent candidate for targeted therapy of JAK2 driven
MPDs.
EXPERIMENTAL PROCEDURES
Samples
Peripheral blood (n = 9) samples, including phlebotomies, were donated on
multiple occasions by patients with PV. Normal cord blood (n = 8) and periph-
eral blood samples (n = 4) were provided by healthy volunteers. Samples wereCancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc. 325
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(A) Schema of Bioluminescent Engraftment Analysis of Human Progenitors in RAG2/gc
/Mice. Normal cord blood or PV progenitor cells were cotransduced
with lentiviral luciferase GFP and backbone, wild-type, or mutant (V617F) JAK2 lentiviral vectors followed by intrahepatic transplantation into neonatal
RAG2/gc
/ mice. Bioluminescence imaging was performed weekly with the aid of a Caliper IVIS Imaging System.
(B) Representative bioluminescence images of mice transplanted with normal HSC, PV HSC, or PV progenitors compared with no transplant controls (n = 4
experiments).
(C) FACS analysis of human erythroid (FSclohuman glycophorin A+CD45/lo) engraftment in spleens ofmice transplanted with normal HSC (upper panel), PV HSC,
and progenitors (lower panel) compared with their untransplanted controls.
(D) Left panel: representative bioluminescent images of mice transplantedwith lentiviral luciferaseGFP-transduced PV (n = 4 separate patients) CD34+ progenitor
cells before (4 weeks posttransplant) and after 12 days of treatment with vehicle or 120 mg/kg of TG101348. Right panel: comparative graph of human erythroid
engraftment (% human Glycophorin A+ Cells in Liver ± SEM) determined by FACS analysis of mice transplanted with PV progenitors and treated with TG101348
compared with vehicle-treated controls.obtained with informed consent according to Stanford University and UCSD
IRB-approved protocols. Normal bone marrow and cord blood samples
were also purchased from All Cells.
Human Hematopoietic Stem Cell and Myeloid
Progenitor Flow-Cytometric Analysis and Cell Sorting
Mononuclear fractions were extracted from peripheral blood or bone marrow
following Ficoll density centrifugation according to standard methods. Sam-
ples were analyzed fresh or subsequent to rapid thawing of samples previously
frozen in 90% fetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO) in
liquid nitrogen. In some cases, CD34+ cells were enriched from mononuclear
fractions with the aid of immunomagnetic beads (CD34+ Progenitor Isolation
Kit, Miltenyi Biotec, Bergisch-Gladbach, Germany) (Jamieson et al., 2004,
2006; Manz et al., 2002) (See Supplemental Experimental Procedures for de-
tails regarding fluorescence-activated cell sorting analysis and sorting of HSC
and myeloid progenitor populations).
Human Hematopoietic Progenitor Assays
Normal and PV HSC (CD34+CD38CD90+Lin), common myeloid progenitors
(CMP; CD34+CD38+IL-3Ralpha+CD45RALin), granulocyte-macrophage
progenitors (GMP; CD34+CD38+IL-3Ralpha+CD45RA+Lin), and megakaryo-
cyte-erythroid progenitors (MEP; CD34+CD38+IL-3RalphaCD45RALin)
were sorted with the aid of a FACS Aria directly into 12 well plates containing
complete methylcellulose (GF+H4435, StemCell Technologies Inc., Vancou-
ver, Canada) according to the manufacturer’s specifications (Jamieson
et al., 2004, 2006) with or without 0, 30, 100, 300, or 600 nM of a selective326 Cancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc.JAK2 inhibitor, TG101348 (TargeGen Inc., San Diego, CA). Colonies were incu-
bated in a 37C 7%CO2 humidified incubator and scored on day 14 as colony-
forming unit mix (CFU-Mix), burst-forming unit erythroid or colony-forming unit
erythroid (BFU-E/CFU-E), CFU-granulocyte (CFU-G), CFU-macrophage
(CFU-M), CFU-megakaryocyte (CFU-Mega), or CFU-granulocyte-macro-
phage (CFU-GM) (Jamieson et al., 2004, 2006). Phase contrast photomicro-
graphs of colonies were obtained on day 14 with a Zeiss Axiovert phase-con-
trast inverted microscope with the aid of SPOT software.
JAK2 Mutation Screening
JAK2V617F mutation genotyping was performed on peripheral blood mono-
nuclear cells derived from patients with PV, as well as normal peripheral blood,
bone marrow, and cord blood. Red blood cells were lysed, and DNA was ex-
tracted with the QiaAmp DNA Blood Mini kit according to the manufacturer’s
directions (QIAGEN, Valencia, CA) and then stored at 80C until amplifica-
tion-based testing. Extracted DNA was prepared for JAK2V617F mutation
analysis by LightCycler methodology as previously described (Jamieson
et al., 2006).
PV Progenitor Colony JAK2 Mutation Analysis
Sequencing analysis of JAK2V617F expression was performed on pooled PV
progenitor colonies treated with vehicle or TG101348. Colonies were plucked
and resuspended in 200 ml of RLT buffer supplemented with b-mercaptoetha-
nol (QIAGEN RNeasy) and frozen immediately at 80C. Samples were
thawed and RNA extracted followed by cDNA preparation and PCR amplifica-
tion with JAK2 specific primers (Jamieson et al., 2006). Mutation analysis of the
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In four experiments, neonatal RAG2/gc
/mice (n = 24; 6mice/group) were transplanted intrahepatically with normal cord blood progenitors that were cotrans-
duced with lentiviral luciferase GFP and a lentiviral backbone vector (BB), wild-type JAK2 (WT JAK2), or JAK2V617F (MUT JAK2) and treated by twice daily oral
gavage for 12 days with vehicle (DMSO) or TG101348 (120 mg/kg). Nontransplanted littermates (no Tp) served as negative controls.
(A) Representative bioluminescence images of transplanted mice before (4 weeks posttransplant), during (day 5 TG101348), and after (day 12 TG101348) treat-
ment with vehicle or TG101348.
(B) FACS analysis of human erythroid (CD45GlycophorinA+) engraftment following treatment with vehicle or TG101348.JAK2 cDNA PCR product was conducted using fluorescent denaturing high
performance liquid chromatography (DHPLC) technology and SURVEYOR
mismatch cleavage analysis both with the WAVE-HS System (Transgenomic,
Gaithersberg, MD). Aliquots of PCR product (3–15 ml) from all samples were
scanned for mutations by DHPLC, confirmed by Surveyor mismatch cleavage,
and identified with bidirectional sequence analysis on an ABI 3100 sequencer
using BigDye V3.1 terminator chemistry (Applied Biosystems, Inc., Foster City,
CA). In addition, for semiquantitative determination of mutant and normal allele
frequencies, relative peak areas of DHPLC elution profiles and Surveyor mis-
match cleavage products were determined after normalization and compari-
son to reference controls using the WAVE Navigator software (Supplemental
Experimental Procedures) (Jamieson et al., 2006).
Lentiviral JAK2 Vector Construction
Wild-type JAK2 and JAK2V617F (3.4 kb) were excised from Jak2-mus-
MSCV-neo at the Not I and Age I sites, blunt-ended, and cloned into the
SmaI site of the self-inactivating lentiviral vector, pLV CMV IRES2 GFP. The
pLV CMV IRES2 GFP was modified from pLV CMV GFP Nhe (Naldini et al.,
1996) by replacing GFP with IRES2GFP (Clontech) (C. Barroga, unpublished
data). Both WT JAK2 and Jak2V617F sequences were verified using murine
Jak2 specific primers flanking the mutation. Lentiviral vectors were simulta-
neously prepared by cotransfection of WT JAK2, JAK2V617F or backbone
vector, together with pCMV-D8.9 and pCMV-VSV-G using Lipofectamine
2000 into 293TFT (Invitrogen, Carlsbad, CA). Viral supernatants were collected
after 48 hr and concentrated by centrifugation. Viral titers of the lentiviral back-
bone varied in the range of 4 3 107 to 1 3 109 iu/ml.
Progenitor Transduction with Lentiviral Vectors
Wild-type JAK2, JAK2V617F, and backbone lentiviral vectors were used to
transduce normal cord blood hematopoietic stem cells (HSC) and progenitor
cells, which were grown in methocult, with (+) or without () TG101348. Colo-
nies were counted at day 14, and RNA was extracted, reversed transcribed,
and amplified withmurine JAK2 specific primers. Sequencing of PCRproducts
confirmed the presence of WT JAK2 and JAK2V617F, respectively.
Bioluminescent Xenogeneic Transplantation Model of Human PV
Immunocompromised RAG2/gc
/ mice were a kind gift from Dr. Irving
Weissman. Mice were bred and maintained on sulfamethoxazole water inthe animal care facility at UCSD Moores Cancer Center. All mouse experi-
ments were performed in accordance with national guidelines and an animal
care protocol (no. S06015) approved by the UCSD Institutional Animal Care
and Use Committee.
To assess engraftment potential and in vivo differentiation capacity,
JAK2V617F+ PV CD34-enriched cells, HSC or progenitors (CD34+CD38+Lin)
were transduced with lentiviral luciferase GFP (Breckpot et al., 2003) for 48 hr
and transplanted intrahepatically into neonatal nonirradiated RAG2/gc
/
mice (Traggiai et al., 2004). Engraftment was analyzed by noninvasive biolumi-
nescent imaging (IVIS 200, Caliper Inc.) and by FACS analysis of hematopoi-
etic tissues. In separate experiments, normal cord blood progenitors were
transduced with lentiviral luciferase GFP together with JAK2 WT-, MT-, and
backbone lentiviral vectors, followed by intrahepatic transplantation into
RAG2/gc
/ mice according to previously published methodology, and an-
alyzed for human engraftment by noninvasive bioluminescent imaging and
FACS (Traggiai et al., 2004). Transplanted RAG2/gc
/ mice were also
treated with a selective JAK2 inhibitor (TG101348, 120 mg/kg) or vehicle
(DMSO) by oral gavage twice daily for 12 days, and the effect on engraftment
was analyzed. In another series of experiments, HSCwere transduced with the
JAK2V617F or backbone lentiviral vector with (+) or without () TG101348 (IN)
or the vehicle (DMSO) and grown for 7 days in myelocult media (Stem Cell
Technologies, Inc.), and transcript levels of erythroid transcription factors
were quantified by Q-PCR (Jamieson et al., 2006).
Inhibition of EPO Signaling in UT7/EPO Cells with TG101348
The human erythro-megakaryocytic cell line, UT7/Epo cells were starved in
0.1% FBS in IMDM for 24 hr prior to stimulation. Cells were preincubated
with various inhibitors including LY294002 (20 mM; Calbiochem, San Diego,
CA), AG490 (50 mM; Calbiochem, San Diego, CA), and TG101348 (300 nM
and 600 nM; TargeGen, San Diego, CA) 1 hr prior to stimulation with 10 U/ml
EPO for 30 min. Cells were lysed with 1% NP40 lysis buffer (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10% glycerol, complete protease
inhibitors and PhosStop; Roche, Indianapolis, IN). Equal amounts of lysate
(20 mg) were loaded in 4%–15% Tris-SDS PAGE gels (Biorad, Hercules, CA)
and probed with phospho-JAK2 (Tyr1007/1008) (Upstate, Millipore, Billerica,
MA), phospho-STAT5 (Tyr694), and phospho-AKT (Ser473) (Cell Signaling,
Danvers, MA), and phospho-GATA-1 (S310) (Abcam, Cambridge, MA). Blots
were stripped and reprobed with anti-JAK2 (Upstate), anti-pAKT (CellCancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc. 327
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(A) Quantitative RT-PCR (Q-PCR) analysis (± SEM) of GATA-1 and PU.1 expression was performed on FACS sorted normal and PV CD34+ progenitor cells.
Results were normalized to human HPRT expression.
(B) Graph demonstrating the GATA-1/PU.1 (left panel) or GATA-1/FOG-1 (right panel) transcript ratios (transcripts normalized to HPRT ± SEM) determined by
Q-PCR following treatment of JAK2V617F (Jak2MT) or backbone (pLV) lentivirally transduced cells with vehicle (DMSO) or TG101348 (300 nM; IN).
(C) Western blot analysis of AKT, GATA-S310, and STAT5 phosphorylation in UT7/EPO cells stimulated with EPO and treated with a PI3 kinase inhibitor,
LY294002 (LY; 20 mM); AG490, a nonselective JAK2 inhibitor (50 mM); or TG101348 (300 or 600 nM).
(D) In a proposed model of the mechanism of inhibition of JAK2-driven erythroid differentiation, TG101348 inhibits JAK2-mediated STAT5 as well as AKT-
mediatedGATA-1 S310 phosphorylation, leading to a potent block in erythroid differentiation following erythropoietin (EPO) binding to the erythropoietin receptor
(EpoR) or activation of signaling through JAK2V617F.Signaling), anti-STAT5 (sc-835) (Santa Cruz Biotechnology, Santa Cruz, CA),
and anti-GATA-1 (Abcam, Cambridge, MA).
Quantitative RT-PCR Analysis of GATA-1, PU.1, and FOG-1
Transcript Levels
Quantitative RT-PCR (Q-PCR) analysis of GATA-1 and PU.1 transcript levels
was performed on FACS-purified PV progenitors as previously described (Ja-
mieson et al., 2006). First, HSC and progenitor (1,000 to 50,000) cells were
sorted directly into RLT Buffer and total RNA was isolated using RNeasy Mi-
cro Kit (QIAGEN, Valencia, CA, USA), according to manufacturer’s protocol
(Jamieson et al., 2006). Then, a SYBR Greener two-step Q-RT-PCR Kit for
the iCycler (Invitrogen, Carlsbad, CA, USA) was used to synthesize cDNA
and assess GATA-1 and PU.1 relative transcript quantities according to the
manufacturer’s protocol. Briefly, 8 ml of 4 to 75 ng/ml of RNA were mixed
with RT Reaction Mix and RT Enzyme Mix and incubated at 25C for 10 min,
followed by 50C for 30 min and finally 85C for 5 min. The tubes were then
chilled and 1 ml of RNase H was added to the reaction followed by a
20 min incubation at 37C. The quantitative PCR (Q-PCR) reaction was per-
formed in duplicate using 2 ml of the template in 25 ml reaction volume con-
taining SYBR Greener Super Mix and 0.4 mM of each forward and reverse
primer. Relative values of transcripts were determined according to a stan-
dard curve. GATA-1 and PU.1 values were then normalized to HPRT values
(for additional details please see Supplemental Experimental Procedures;
Jamieson et al., 2006).
Statistical Analysis
Standard deviation (SD), standard error of the mean (SEM), and numbers of
HSC and progenitors per 105 mononuclear cells were measured using FlowJo328 Cancer Cell 13, 321–330, April 2008 ª2008 Elsevier Inc.and Excel software. A two-tailed Student’s t Test (Excel software) was used to
analyze statistical differences in the types of colonies derived from PV patient
samples treated with vehicle or TG101348 as well as engraftment rates in
RAG2/gc
/ mice. A two-tailed t test (InStat and software) was used to an-
alyze statistical differences in transcript levels of JAK2V617F transduced
CD34 treated with vehicle or TG101348.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/4/321/DC1/.
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